As part of the Australian government’s response to its Review of Medicines and Medical Devices Regulation (MMDR Review), TGA announced the implementation of a priority review pathway for the registration of novel prescription medicines for Australian patients. The eligibility criteria are: • serious condition • comparison against existing therapeutic goods, and • major therapeutic advance.
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
